KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Invested Capital (2016 - 2025)

Historic Invested Capital for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $147.4 million.

  • Rigel Pharmaceuticals' Invested Capital rose 110690.08% to $147.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.4 million, marking a year-over-year increase of 110690.08%. This contributed to the annual value of $10.6 million for FY2024, which is 14931.12% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Invested Capital stood at $147.4 million for Q3 2025, which was up 110690.08% from $104.3 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Invested Capital peaked at $147.4 million during Q3 2025, and registered a low of -$31.8 million during Q3 2023.
  • Its 5-year average for Invested Capital is $17.1 million, with a median of -$3.7 million in 2022.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Invested Capital crashed by 66461.79% in 2023 and then surged by 110690.08% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Invested Capital (Quarter) stood at $30.4 million in 2021, then plummeted by 144.83% to -$13.6 million in 2022, then crashed by 57.28% to -$21.4 million in 2023, then surged by 149.31% to $10.6 million in 2024, then skyrocketed by 1295.55% to $147.4 million in 2025.
  • Its Invested Capital stands at $147.4 million for Q3 2025, versus $104.3 million for Q2 2025 and $33.4 million for Q1 2025.